Castle Biosciences, Inc. (NASDAQ:CSTL – Get Rating) insider Derek J. Maetzold sold 2,869 shares of the business’s stock in a transaction dated Monday, November 21st. The stock was sold at an average price of $20.84, for a total value of $59,789.96. Following the sale, the insider now owns 289,520 shares in the company, valued at $6,033,596.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Castle Biosciences Stock Down 0.0 %
Shares of CSTL stock traded down $0.01 on Thursday, hitting $21.07. 132,886 shares of the stock were exchanged, compared to its average volume of 240,834. Castle Biosciences, Inc. has a one year low of $15.58 and a one year high of $48.40. The firm’s 50 day moving average is $23.87 and its two-hundred day moving average is $24.53.
Analysts Set New Price Targets
CSTL has been the topic of several analyst reports. Robert W. Baird reduced their target price on Castle Biosciences from $48.00 to $41.00 and set an “outperform” rating on the stock in a report on Thursday, November 3rd. SVB Leerink upped their target price on Castle Biosciences from $45.00 to $50.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 9th. Finally, BTIG Research increased their price target on Castle Biosciences to $47.00 in a research report on Monday, August 15th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $57.86.
Institutional Trading of Castle Biosciences
Castle Biosciences Company Profile
Castle Biosciences, Inc, a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.
- Get a free copy of the StockNews.com research report on Castle Biosciences (CSTL)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.